Advaxis Awarded Best Therapeutic Vaccine

Advaxis Awarded Best Therapeutic Vaccine
Presented at the 5th Annual Vaccine Industry Excellence Awards

PRINCETON, N.J., Apr 12, 2012 (BUSINESS WIRE) -- Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards for its ADXS-HPV construct. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months.

Advaxis' ADXS-HPV construct is in Phase 2 development for the treatment of cervical intraepithelial neoplasia (CIN) 2/3, recurrent/refractory cervical cancer, and head and neck cancer. Of the four Phase 2 trials, Advaxis is sponsoring a CIN 2/3 trial in the US and a recurrent/refractory cervical cancer trial in India. The Gynecologic Oncology Group (GOG), a division of the National Cancer Institute, is sponsoring a US study in recurrent/refractory cervical cancer and Cancer Research UK (CRUK) is sponsoring a trial in head and neck cancer in the United Kingdom.

"We are delighted to receive recognition for our Company's achievements in developing ADXS-HPV," commented Thomas A. Moore, Chairman & CEO of Advaxis. "Our team continues to bring our proprietary platform technology from the laboratory into the clinic and meet major milestones in development in HPV caused cancers and soon in prostate and breast cancer, as well."

The ViE Awards

The ViE Award nominees were voted on by those in the global vaccine industry and also judged by a panel of representatives from pharma, biotech, academia, government, non-governmental organizations (NGOs), and public health. Winners were announced at the annual ViE Awards on April 11, 2012 during the World Vaccine Congress in Washington, D.C., produced by Terrapinn.

The criteria used to judge this category are as follows:

-- Vaccine candidate addresses current unmet medical needs

-- Candidate shows significant potential for vast geographical and market reach

-- Candidate possesses a novel mode of action or technology

-- Progress made to date through clinical trials and/or achieved milestones

-- Advanced efficacy, safety, and risk management data where appropriate

A full list of award winners is available at the World Vaccine Congress website.

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

Advaxis' lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (CRUK study). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research -- UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at www.sec.gov . The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

SOURCE: Advaxis, Inc.


       
        Advaxis, Inc.
        Diana Moore, 609-452-9814
        Director, Investor Relations & Business Development
        [email protected]
      

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.